Apollomics Inc. (APLM) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Welcome to the Appleomics full year 2023 results conference call. Before we begin, we want to advise you that over the course of the call and question and answer session, forward-looking statements will be made regarding events, trends, business prospects, and financial performance, which may affect Appleomics future operating results and financial position. All such statements are subject to risk and uncertainties, including the risk and uncertainties described under the risk factors section included in APALOMIC's annual report on Form 20F, registration statement on Form F1, and other reports filed with the Securities and Exchange Commission. APALOMIC advises you to review these risk factors in considering such statements. APALOMIC assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the dates they are made. It is now my pleasure to turn the floor over to Dr. Guoliang Yu, Appleomics Chairman and Chief Executive Officer. Sir, you may begin. Thank you, Shannon. Good morning, everyone, and thank you for taking the time to join us today as we provide an overview of recent business highlights and discuss our four-year 2023 financial results. Joining me for the call today is Dr. Sanjeev Radhika, our President, Dr. Peony Yu, our chief medical officer, and Dr. Matthew Plunkett, our recently appointed chief financial officer who joined us earlier this month. Matt brings to Appleomics an outstanding track record of executive leadership in financial strategy and business development. We look forward to his contributions as we continue to execute on our vision of bringing Vibratinib or APL-101 and our other pipeline candidates towards regulatory approvals to better serv...